MOSCOW (MRC) -- All closing conditions on the path toward Siegfried's acquisition of BASF's pharmaceutical supply business have been fulfilled. They include regulatory assurance issued by Swissmedic that the necessary approval for the Evionnaz production site will be provided in time for the closing, as per 4-traders.
Siegfried assumes that the agreements between Siegfried and BASF (closing) and the connected transfer of the chemical-pharmaceutical production sites in France, Germany and Switzerland will be enforced as planned on September 30, 2015.
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Germany, China, Malta and in the USA. At the end of 2014, Siegfried reported annual sales of CHF 315 million and employs at the time being approximately 1400 employees. Siegfried Holding AG is listed on the Swiss Exchange.
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.
As MRC informed earlier, BASF began its first production of diphenylmethane diisocyanate (MDI) at its wholly-owned site in Chongqing, China. Production will be ramped up gradually in line with market demand.
BASF is the largest diversified chemical company in the world and is headquartered in Ludwigshafen, Germany. BASF produces a wide range of chemicals, for example solvents, amines, resins, glues, electronic-grade chemicals, industrial gases, basic petrochemicals and inorganic chemicals. The most important customers for this segment are the pharmaceutical, construction, textile and automotive industries. BASF had sales of over EUR74 billion in 2014 and over 113,000 employees as of the end of the year.
MRC